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ABSTRACT 
YKL-40 is a member of mammalian chitanase (CHI3L1), expressed and secreted 
by several types of  solid tumor cells, inflammatory cells and stem  cells. The 
precise  physiological  role  of  YKL-40  in  cancer  is  still  not  clear  and  it  is 
suggested that it play a role in cancer cell proliferation, differentiation, metastatic 
potential, cell attachment and migration, reorganization and tissue remodeling. 
The aim of the study was to check the appearance of YKL-40 in leukemic cells 
and over-expression of YKL-40 in the plasma of leukemia patients in comparison 
to  healthy  controls,  and  find  whether  YKL-40  could  serve  as  a  peripheral 
biomarker for leukemia. The study was conducted between July 2012 and March 
2013 and included 67 volunteers, 55 having leukemia at the stage of diagnosis of 
the disease and 12 normal healthy volunteers. YKL-40 levels were determined in 
all  plasma  samples  using  the  YKL-40  enzyme-linked  immunosorbent  assay 
(ELISA)  kit  and  expression  of  YKL-40  was  observed  by  using 
immunocytochemical  (ICC)  analysis.  YKL-40  plasma  levels  differed 
significantly between patients with leukemia and the normal healthy volunteers 
(P=<0.001) and YKL-40 was positively expressed in all four types of leukemia 
(AML, ALL, CLL and CML) specimens. 
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Introduction 
YKL-40 is an inflammatory glycoprotein associated with 
mammalian chitanase-like proteins (CHI3L1). It is expressed 
and oozed by some types of solid tumor cells, inflammatory 
cells and stem cells. The plasma/serum YKL-40 level is often 
elevated in patients with disease depicted by inflammation, 
like  some  types  of  infections  compared  to  normal  healthy 
volunteers (Cintin et al., 2002; Johansen et al., 2004). The 
physiological  role  of  YKL-40  in  cancer  is  not  clear 
(Johansen, 2006) and it has been suggested that it play a role 
in  differentiation,  overgrowth  cancer  cell,  cell  attachment, 
metastatic  potential,  cell  migration,  tissue  remodeling  and 
tissue reorganization(De Ceuninck et al., 2001; Recklies et 
al., 2002; Ling & Recklies, 2004). 
It was first time reveal in whey secretions of non-lactating 
cows. Human YKL-40 contains a single polypeptide chain of 
383 amino acids, molecular mass of 40.4 KDa (Hakala et al., 
1993)  and  an  isoelectric  point  about  7.6  (Renkema  et  al., 
1998). 
Amino  acid  sequence  analysis  reveals  that  YKL-40 
belongs to the glycosyl hydrolase [chitinase protein] family 
18 (Henrissat & Bairoch, 1993), but it does not has chitinase 
function.  On  the  basis  of  its  three  N-terminal  amino  acids 
tyrosine  (Y),  lysine  (K)  and  leucine  (L)  and  its  molecular 
mass of 40 kDa, the protein was named YKL-40 (Johansen et 
al.,  1992).  In  the  human,  the  gene  encoding  YKL-40 
glycoprotein was discovered in 1997 (Rehli et al., 1997). It is 
located on chromosome 1q32.1, has a size of 7.948 kp and 
contain of 10 exons. Two splice forms of the YKL-40 gene 
are reported: isoform 1 that contains axon 1-10 and isoform 
2, where axon 8 is spliced out (Rehli et al., 2003). ISSN: 1314-6246  Hurmale et al.  J. BioSci. Biotech. 2013, 2(3): 215-220. 
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Several clinical analysis of patients with distinct types of 
cancer revealed that the higher concentration of YKL-40 in 
serum also seems to correlate with poor prognosis and short 
survival  in  some  types  of  cancers  including  ovary,  breast, 
glioblastoma melanoma and colorectal cancer (Cintin et al., 
2002; Johansen et al., 2003; Johansen, 2006; Roslind et al., 
2008; Hogdall et al., 2009). YKL-40 protein expression has 
not been evaluated in tissue from patients with leukemia and 
lymphoma.  In  myeloma,  YKL-40  arises  from  cells  in  the 
bone  marrow  microenvironment  surrounding  the  mye loma 
cells (Mylin et al., 2009; Schultz & Johansen, 2010). 
The  purpose  of  this  study  was  to   explore  the  clinical 
usefulness of YKL-40 in leukemia and to examine the plasma 
level of YKL-40 in leukemic patients (ALL, AML, CLL, and 
CML) and normal volunteers using enzyme linked immune-
sorbent  assay  (ELISA)  and  also  studied  the  expression  of 
YKL-40 by immunocytochemistry assay. 
Patients and Methods 
Patients 
The study included 67 volunteers, 55 having leukemia at 
the stage of diagnosis of the disease and 12 normal healthy 
volunteers. The healthy subjects were not on medication, and 
had  no  signs  or  clinical  symptoms  of  cancer,  joint,  liver, 
metabolic or endocrine diseases. Out of 55 leukemic patients, 
18  patients  had  acute  lymphocytic  leukemia  (ALL),  6  had 
acute myeloid leukemia (AML), 4 had chronic lymphocytic 
leukemia and 27 had chronic myeloid leukemia (CML).  A 
written informed consent was obtained from patients before 
study  entry,  which  was  approved  by  the  review  board  of 
Regional Cancer Hospital, Bhopal. From every patients and 
healthy volunteers, 5 ml of blood were taken by a vacutainer 
system with EDTA. 
Analysis of YKL-40 plasma levels 
YKL-40  levels  were  determined  in  all  plasma  samples 
using  the  YKL-40  enzyme-linked  immunosorbent  assay 
(ELISA)  kit  according  to  the  manufacturer  instructions 
(BlueGene  Biotech,  Shanghai).  The  ELISA  assay  for  the 
quantitative measument of YKL-40 utilized a polyclonal anti-
YKL-40  antibody  and  YKL-40-HRP  conjugate.  The  assay 
sample  and  buffer  were  incubated  together  with  YKL-40-
HRP  conjugate  in  pre-coated  plate  for  one  hour.  Then  the 
wells were incubated with a substrate for HRP enzyme. The 
product  of  the  enzyme-substrate  reaction  formed  a  blue 
colored complex. Finally, a stop solution was added to stop 
the reaction, which was then turned the solution yellow. The 
intensity  of  color  was  measured  spectrophotometrically  at 
450  nm  in  a  microplate  reader.  Concurrent  standards  of 
known YKL-40 were run and a standard curve was plotted 
relating the intensity of the color (O.D.) to the concentration 
of YKL-40. The detection limit of the YKL-40 ELISA assay 
was 20.0 ng/ml 
Immunocytochemistry for YKL-40/CHI3L1 
Immunocytochemical (ICC) analysis for YKL-40 antigen 
was  carried  out  on  randomly  selected  samples  of  each 
leukemic  group.  ICC  analysis  was  performed  directly  on 
slides with blood smear. The ICC procedures were performed 
by fixation and permeabilization in chilled methanol-acetone 
mixture  at  -20°C.  Endogenous  peroxidase  blocking  was 
performed  using  3%  H2O2  in  PBS  and  blocking  of  non-
specific  binding  was  done  by  5%  BSA  in  PBS.  The 
antibodies  used  in  this  study  were  GP39  rabbit  polyclonal 
IgG (diluted 1:1000) and goat anti-rabbit IgG-HRP (diluted 
in  1%  BSA,  1:1000).  The  color  of  immunostaining  was 
developed  by  chromogenic  substrate  (TMB  substrate 
solution). After color development, the slides were analyzed 
under magnification 40x by using inverted light microscope 
(Leica, Germany). 
Results 
Average values of the YKL-40 plasma level from patients 
with  different  types  of  leukemia  and  from  normal  healthy 
volunteers are shown in Table 1. The geometric mean and 
median  of  plasma  YKL-40  level  in  leukemia  patients  was 
180.55 (AML 170.91, ALL 168.65, CLL 211.21, and CML 
186.09)  and  in  normal  volunteers  was  108.25  and  173.03 
(AML 171.90, ALL 171.27, CLL 194.23 and 173.03) (Table 
1 and Table 2). Immunocytochemistry analysis showed that 
YKL-40  was  positively  expressed  in  all  four  types  of 
leukemia (AML, ALL, CLL and CML) specimens (Figure 1). 
Distribution of YKL-40 levels and determination of cut-off 
value  
Plasma  YKL-40  levels  in  each  group  were  normally 
distributed. The geometric mean and median YKL-40 levels 
for the normal control groups were 108.25 ng/ml and 112.25 
ng/ml,  respectively  (range  72.40–153.81  ng/ml).  These 
values are consistent with those given in the manufacturer’s 
instructions (Blue Gene Biotech). 
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Table 1. Descriptive statistics of YKL-40 plasma levels in the different groups. 
 
Subgroup  Size  Mean 
(ng/ml) 
SE  Max 
(ng/ml) 
Min 
(ng/ml) 
CI of 
Mean 
Range  Median 
(ng/ml) 
90% 
Healthy  12  108.25  1.04  153.81  72.40  15.49  81.41  112.25  112.00 
AML  6  170.31  10.63  200.17  131.62  27.32  68.55  171.90  196.77 
ALL  18  168.65  11.27  270.83  109.45  23.79  161.38  171.27  203.28 
CLL  4  211.21  27.25  288.91  167.47  86.72  121.44  194.23  248.49 
CML  27  186.09  9.26  317.93  117.06  19.05  200.87  173.03  212.06 
All Leukemia  55  180.55  6.33  317.93  109.45  12.07  208.48  173.03  203.65 
SE= Standard Error, CI= Confidence Interval 
 
Table 2. ANOVA (Duncan's and Dunnett's Test) for YKL-40 plasma levels of leukemia patients versus normal healthy volunteers. 
 
Group Name  N  Mean  
(ng/ml 
SD  SEM  Difference of 
Mean 
q  P<0.05 
AML  6  170.91  26.04  19.535  60.40  3.027  Yes 
ALL  18  168.65  47.85  6.138  62.66  4.213  Yes 
CLL  4  211.21  54.50  27.250  102.96  4.469  Yes 
CML  27  186.90  48.16  9.268  77.84  5.622  Yes 
All Leukemia  55  180.55  46.69  6.3.36  73.03  6.336  Yes 
N = Number or Patients, SD = Standard Deviation, SEM = Standard Error of Mean, Yes = statistically significant differences. 
 
 
The  90
th  percentile  of  YKL-40  values  for  the  normal 
control  group,  112.00  ng/ml  (Prism  GraphPad  5.03),  was 
used as the cut-off value for the analyses (Figure 2). YKL-40 
plasma  levels  differed  significantly  between  patients  of 
leukemia  (Leukemia)  and  the  normal  healthy  volunteers 
(ANOVA, P=<0.001). From Duncan’s and Dunnett’s test it 
was  found  that  the  mean  of  YKL-40  plasma  levels  in  the 
leukemia  patients  (AML.  ALL,  CLL  and  CML)  was 
significantly  higher  than  the  means  found  in  the  normal 
healthy volunteers (P<0.05).  
Analysis of Variance (ANOVA) 
Using t-test and one way ANOVA analysis it was found 
that the differences in the mean values of plasma YKL-40 
level  between  the  leukemia  patients  and  normal  healthy 
volunteers  was  greater than  would be expected by chance. 
There  is  a  statistically  significant  differences  P=<0.05 
(t=5.139) (Table 2). 
The differences in the mean values between the chronic 
(CLL and CML) and acute (ALL and AML) leukemia were 
not statically significant (P=0.116) due to random sampling 
variability (t=1.597). 
Discussion 
Over  the  last  two  decades,  promising  data  have 
established that YKL-40, a secreted glycoprotein, elevated in 
a broad spectrum of human diseases including liver damage, 
asthma,  diabetes,  some  inflammatory  diseases,  cardiac 
disorders and cancer (Shao et al., 2009; Francescone et al., 
2011). 
In the present study, we demonstrated that plasma YKL-
40 level was elevated in all four types of leukemia: AML 6 
(100%) out of 6, ALL 15 (83%) out of 18, CLL 4 (100%) out 
of 4 and CML 27 (100%) out of 27 (Figure 2 and Figure 3). It 
is also consistent with previous findings that plasma/serum 
YKL-40  level  is  increased  in  several  types  of  cancer  and 
solid tumors with a variety of histological types (Johansen et 
al.,  2003;  Mitsuhashi  et  al.,  2009)  such  as  it  was 
overexpressed  in  42  (58.3%)  out  of  74  epithelial  ovarian 
cancer  specimens (Yang et al., 2010). 
Pretreatment YKL-40 was above the cut-off level in 75% 
(78 of 104) of patients with squamous cell carcinoma (SCC) 
of  the  cervix  and  78%  (29  of  37)  of  those  with 
adenocarcinoma  (Mitsuhashi  et  al.,  2009),    In  colorectal 
cancer, the median preoperative serum/plasma YKL-40 level 
in 603 patients was 180 ng/mL (range 56-2709 ng/mL) and 
16% of the Dukes’ A patients, 26% with Dukes’ B, 19% with 
Dukes’  C  and  39%  with  Dukes’  D  had  overexpression  of 
YKL-40 protein (Dehn et al., 2003). YKL-40 secretion was 
also found in human lactating mammary  gland (Roslind et 
al., 2008). 
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Figure 1. Immunocytochemical analysis of all four leukemia [(A) AML (B) ALL (C) CLL and (D) CML] blood smear shows the 
positive expression and indicate the presence of chitinase like protein YKL-40. 
 
 
Figure 2.(A) Graph showing the point plot of plasma YKL-40 mean value of normal healthy volunteers and patients with 
different types of leukemia. Long horizontal lines - mean values; Short horizontal lines - standard deviations; (B) Point plot of 
plasma YKL-40 median value with interquartile in patients with leukemia and control healthy group patients. Horizontal 
dotted line - 90
th percentile of healthy controls. ISSN: 1314-6246  Hurmale et al.  J. BioSci. Biotech. 2013, 2(3): 215-220. 
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Figure 3: (A) Diagram of mean with SEM of plasma YKL-40 levesl (B) Mean and SD with error bars. 
 
In  our  study,  we  found  that  YKL-40  was  positively 
expressed in all four blood smear of leukemia (AML, ALL, 
CLL  and  CML)  using  immunocytochemistry  analysis.  For 
this study randomly selected, one blood sample of each group 
(AML,  ALL,  CLL  and  CML)  were  used  for 
immunocytochemical expression of YKL-40 on blood smear 
slides (Figure 1) and it was confirmed that biologically active 
YKL-40 protein produced by cancerous cells in all four types 
of leukemia patients. 
In previous study, the expression of YKL-40 was found in 
synovial  cells,  articular  cartilage  chondrocytes  and  raise 
considerably  in  a  variety  of  tumors  and  cell  lines  derived 
from  kind  of  tumors,  such  as  tumors  of  the  bone,  brain, 
breast,  lung  (Johansen  et  al.,  2004),  and  ovary  (Johansen, 
2006; Hogdall et al., 2009). At the cellular level, YKL-40 
protein  expression  is  high  in  embryonic  and  fetal  tissues 
characterized  by  rapid  proliferation  and  marked 
differentiation  and  in  tissues  undergoing  morphogenetic 
changes  (Johansen  et  al.,  2007;  Kim  et  al.,  2007). 
Overexpression of CHI3L1on the protein level in HEK 293 
cell line was confirmed by immunofluorescence and Western 
blot  analysis  (Kavsan  et  al.,  2011)  and  its  expression  was 
absent in subset of glioblastomas termed “proneural”, which 
comprise up to 30% of all  glioblastomas, due to promoter 
hypermethylation (Noushmehr et al., 2010). 
Our study shows that plasma level of YKL-40 have a high 
sensitivity for leukemia, and determination of plasma YKL-
40 can be used as a prognostic marker for the existence of 
leukemia. We confirmed that, overexpression of plasmaYKL-
40  was  frequently  noticed  in  patients  with  leukemia. 
Consequently, we assume that higher-expression of YKL-40 
protein  in  leukemiaous  or  leukemic  patients  may  promote 
tumorigenesis or cancer progression and the plasma level of 
YKL-40 was elevated through increasing extracellular matrix 
degradation. 
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